Palvella Therapeutics has appointed Matt Pauls, a rare disease biotech executive with over 25 years of experience, to its Board of Directors. Pauls currently serves as Chair and CEO of Savara Inc. and previously led Strongbridge Biopharma through its IPO and the commercialization of KEVEYIS and Macrilen. He also held senior commercial roles at Insmed, Shire, Bristol Myers Squibb, and Johnson & Johnson, and served on the Board of Soleno Therapeutics through its $2.9 billion acquisition by Neurocrine Biosciences in 2026. Palvella is preparing for the potential U.S. launch of its lead product candidate QTORIN rapamycin for serious, rare skin diseases and vascular malformations with no FDA-approved therapies.
Palvella Therapeutics, IncAppointment of experienced rare disease executive to board strengthens leadership ahead of potential product launch.
Insmed Inc
Savara Inc
Pelthos Therapeutics Inc.